Related Experiment Video
Updated: Dec 6, 2025

23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
8.3K
Bridging the geroscience chasm between bench and bedside.
Ericka E Tung1, Karen M Weavers2, James L Kirkland3
1Division of Community Internal Medicine, Division of Geriatric Medicine and Gerontology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
Gerontology & Geriatrics Education
|October 9, 2020
Summary
This program trains aging science scholars in geroscience research and clinical trials. It offers a feasible, scalable solution to the training gap in geriatric medicine.
Area of Science:
- Geriatric Medicine
- Aging Research
- Translational Science
Background:
- Geroscience therapeutics hold promise for geriatric medicine.
- A significant gap exists in training for geroscience trial design and implementation.
- Existing training programs lack comprehensive curricula for aging science scholars.
Purpose of the Study:
- To present a novel 2-year geroscience training program.
- To address the identified training gap in aging research.
- To establish a prototype for future academic aging centers.
Main Methods:
- Developed a 2-year curriculum with two distinct training tracks.
- Incorporated coursework, clinical experiences, and mentored translational research.
- Leveraged existing clinical and research training infrastructures.
Main Results:
- The program provides scholars with fundamental aging research knowledge.
- Scholars gain practical experience through mentored translational projects.
- The curriculum includes diverse learning modalities like discussions and lab work.
Conclusions:
- The developed geroscience training program is feasible and scalable.
- This program can serve as a prototype for other institutions.
- It addresses the critical need for skilled geroscience researchers.
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
70
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
70
Preclinical Development: Overview
5.6K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.6K
Bias in Epidemiological Studies
1.1K
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:
1.1K
Crossing Over
161.2K
Unlike mitosis, meiosis aims for genetic diversity in its creation of haploid gametes. Dividing germ cells first begin this process in prophase I, where each chromosome—replicated in S phase—is now composed of two sister chromatids (identical copies) joined centrally.
The homologous pairs of sister chromosomes—one from the maternal and one from the paternal genome—then begin to align alongside each other lengthwise, matching corresponding DNA positions in a process...
The homologous pairs of sister chromosomes—one from the maternal and one from the paternal genome—then begin to align alongside each other lengthwise, matching corresponding DNA positions in a process...
161.2K
Bioequivalence: Overview
1.5K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.5K

